AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03468257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pavlovian Conditioning
Description: Imagining a stressful event, engaging in progressive muscle relaxation, and eating fruit
Study NCT03886350 — intervention group
Intervention type: OTHER
Intervention: blood and sputum samples
Description: Blood and sputum samples for research purpose collected during routine tests performed at steady state and acute exacerbation
Study NCT03966703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mixing analysing test
Description: The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency
Study NCT00789451 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
Study NCT02682589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: 3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
Study NCT00964340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
Study NCT01265173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 400 mg
Study NCT04101227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD04 (ondansetron)
Description: AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)
Study NCT04101227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
Study NCT04101227 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Companion Diagnostic for Genetic Testing
Description: Companion Diagnostic for Genetic Testing
Study NCT00964340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
Study NCT00964340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
Study NCT02083705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CC+SI
Description: Chest compression will be superimposed by sustained inflation during CPR
Study NCT02083705 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3:1 CPR
Description: CPR using 3:1 ratio (control group)
Study NCT03834519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03834519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Oral tablets
Study NCT03834519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate
Description: Oral tablets
Study NCT03834519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral tablets
Study NCT03834519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Oral tablets or oral capsules
Study NCT03834519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral tablets
Study NCT04132518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra
Description: Initial injection and optional 3 injections with Sculptra in Midface.
Study NCT02783040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT02783040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study NCT02783040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT00789451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
Study NCT03527966 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 5cc Vivigen and local autograft
Description: The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft
Study NCT03527966 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Small kit rhBMP-2 with local autograft
Description: The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft
Study NCT05442320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)
Description: Toothpaste with 500 or 1000 ppm of fluoride
Study NCT05442320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)
Description: Toothpaste with 500 or 1000 ppm of fluoride
Study NCT04101227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Companion Diagnostic for Genetic Testing
Description: Companion Diagnostic for Genetic Testing
Study NCT04101227 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Psychological Counseling
Description: Brief Psychological Counseling
Study NCT04101227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Psychological Counseling
Description: Brief Psychological Counseling
Study NCT00656799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
Study NCT00656799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
Study NCT02783040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT02783040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Study NCT02924714 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Discontinuation of imatinib
Study NCT05186701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Kinesio tape was applied with mechanical correction technique having I shaped with 50-100% tension for 72 hours on both shoulders in retracted position from the anterior aspect of the acromion to the spinous process of the 10th thoracic vertebra of the both shoulders.~Conventional Physical; Therapy:~Thermotherapy (hot pack) applied for 10 minutes. Myofacial release. Active isolated unilateral stretching of pectoralis minor muscle for 30 seconds (3 set × 3 reps/day).~Strengthening of shoulder retractors (lower trapezius and rhomboids). (3 set × 15 reps/day).~Participants were asked to do exercises at home on daily basis.
Study NCT05186701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional Treatment: Hot pack, Myofascial Releaase, Stretching and Strengthening with Theraband
Study NCT01636388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic donor derived LMP specific cytotoxic T-lymphocyte
Description: LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
Study NCT02233738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (GMI)
Description: Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
Study NCT02233738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Treatment Condition (CT)
Description: Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance.
Study NCT03186079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiaojidaozhi Decoction
Description: Mixture of twelve Chinese herbal medicines granule
Study NCT03186079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mixture of 10% Chinese herbal medicines granule and 90% artificial gum
Study NCT03186079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiberform
Description: Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
Study NCT03186079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fiberform
Description: Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
Study NCT03186079 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Toilet training
Description: Toilet training has been considered a routine method in treatment of constipation
Study NCT03423628 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Arm A: 35 Gy of Intensity-modulated radiation therapy (IMRT) administered at daily fractions of 3.5 Gy over 10 fractions (2 weeks) Arm B: 30 Gy of whole brain radiation therapy (WBRT) or partial brain radiation therapy (PBRT) administered at daily fractions of 3 Gy over 10 fractions (2 weeks).~\*\*Arm B has now closed to recruitment\*\* Arm C: 60 Gy of intensity-modulated radiation therapy (IMRT) administered at daily fractions of 2 Gy over 30 fractions (6 weeks)
Study NCT03423628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1390
Description: AZD1390 Administered in 3 Cycles depending on arm:~Cycle 0 (arms A and C): 1 dose prior to Radiation Therapy. For optional food effect assessment in Arm A, 2 doses prior to RT under both fed and fasted conditions. \*Note: the optional food effect assessment is currently not open to recruitment\*.~Cycle 1 (all arms): Intermittent or continuous dosing during Radiation Therapy (except for first 2 cohorts of Arm A).~Cycle 2 (arms A and C): 2 weeks adjuvant treatment after Radiation Therapy.
Study NCT00795522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine
Study NCT02478801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: amino acids intake
Description: amino acids intakes will be varied at 0.2-2.8 g/kg/day
Study NCT00937157 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Copaxone
Description: 12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
Study NCT04246294 — intervention group
Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP is golden standard treatment for moderate-to-severe sleep apnea with high compliance, effectiveness, and cost-effectiveness.~There will be no interference with standard care.
Study NCT02225990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group, Sub-Acute
Description: For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
Study NCT02225990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group, Chronic
Description: For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
Study NCT02225990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care, Sub-Acute
Description: This group will receive standard of care stroke rehabilitation therapy.
Study NCT02225990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care, Chronic
Description: This group will receive standard of care stroke rehabilitation therapy.
Study NCT02943720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AllerT
Description: Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
Study NCT02943720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02969304 — intervention group
Intervention type: DRUG
Intervention: dimethyl fumarate
Description: Off-Label Use: All participants \<18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate~On-Label Use: All participants >18 years of age with an MS diagnosis who are prescribed dimethyl fumarate
Study NCT03884218 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Infra red thermal imaging
Description: thermal image using a non-touch, non-ionising, thermal camera system
Study NCT00558025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Extended Release
Study NCT00558025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Immediate Release
Study NCT02646280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
Study NCT02646280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
Study NCT02646280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive rehabilitation
Description: Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
Study NCT00649701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Text-Based Prevention Web Page
Description: A link to the CDC.gov web page which describes HIV prevention among men who have sex with men.
Study NCT00649701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Morning After
Description: A dramatic video about 4 gay men addressing sexual risk reduction within the context of alcohol use.
Study NCT00649701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking About HIV
Description: A documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use.
Study NCT00649701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Both Videos
Description: Morning After and Talking About HIV videos
Study NCT01846507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
Study NCT02187250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Study NCT02187250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Study NCT02187250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: roflumilast
Study NCT01072812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posiphen® tartrate capsules
Description: Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
Study NCT01980914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPro2 glucose sensor attachment
Description: At the same time the glucose sensor is started, a trained research nurse will connect the patient to an Icentia CardioSTAT, a continuous ambulatory ECG cardiac monitor.
Study NCT02946645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Bite (orthotic/sub-lingual)
Description: Bite is a device which simulates a set of properly positioned teeth
Study NCT02946645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Physiotherapy
Description: Mandibular Stabilisation Exercises~1. Place knuckle of index finger between top and bottom teeth.~2. Remove it, keeping the teeth separated one-knuckle apart.~3. Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above.
Study NCT02946645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No interventions.
Study NCT01121887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Telephone-based smoking cessation counselling based on a combination of coaching and cognitive behavioural therapy (CBT) techniques. Counsellors are also trained in giving tailored advice regarding the use of smoking cessation aids.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge.
Study NCT01121887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Telephone-based smoking cessation counselling with Motivational Interviewing added to the standard treatment protocol.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge.
Study NCT00549523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing 0 mg bid (placebo)
Study NCT00549523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose
Description: Capsules containing 400 mg bid of L. frutescens.
Study NCT00549523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid Dose
Description: Capsules containing 800 mg bid of L. frutescens.
Study NCT00549523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose
Description: Capsules containing 1200 mg bid of L. frutescens.
Study NCT04464122 — intervention group
Intervention type: DRUG
Intervention: Somatostatin analog; chemotherapy
Description: According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.
Study NCT04035928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D digital scanning for maxillofacial prosthetics
Description: The non-invasive Artec Space Spider 3D scanner will be used to image the indicated areas of the patients head and face. In the case of an intraoral defect, the noninvasive TRIOS intraoral 3D scanner will be used. The study may also use nasometry or nasal endoscopy to measure the amount of airflow through the patient's fistula to help guide the design. The software that will be used will create a 3D image of the prosthesis during the patient's clinic appointment. Once a model of the prosthesis is fully designed and manufactured, the patient will return to clinic for a second appointment which may involve fitting and coloring. A subsequent appointment will involve delivery of a successfully fitted and colored prosthesis that the patient will take home.
Study NCT02551731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: 20 or 40 mg/kg/day BID
Study NCT02950454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: 1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer